Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

73.06 +1.42 (+1.98%)
Streaming Delayed Price Updated: 3:37 PM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
32 33 Next >
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
Revisiting the Biggest Winners and Losers Since the COVID Crash Low
A look at how the average stock that’s currently in the S&P 1500 has done since the Covid crash low by sector. 
Via Talk Markets
Gilead Shares Updated Data From Remdesivir Study In Pediatric COVID-19 Patients
Gilead Sciences Inc (NASDAQ: GILD) announced new data from an interim analysis of its ongoing, Phase 2/3 study of Veklury (remdesivir) in pediatric patients... 
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate... 
Via Talk Markets
Gilead Sciences: Q4 Earnings Insights
Gilead Sciences (NASDAQ:GILD) reported its Q4 earnings results on Tuesday, February 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Gilead to Report Q4 Earnings: Is a Beat in the Cards?
Biotech major Gilead Sciences Inc.is slated to report fourth-quarter 2021 results on Feb 1, after market close. 
Via Talk Markets
What 5 Analyst Ratings Have To Say About Gilead Sciences
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: 
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, Here's How Much You Would Have Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.4% on an annualized basis. 
Via Benzinga
Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron
Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) has demonstrated in vitro activity against ten SARS-CoV-2 variants, including omicron. The... 
Via Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. 
Via Investor's Business Daily
FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings
The  
Via Benzinga
The 7 Highest Dividend Stocks for Income Investors
These dividend stocks, including SCCO stock and CQP stock, offer high yields, a proven track record and high ratings in Dividend Grader. 
Via InvestorPlace
Glaxo's Q4 Pharma Sales Jump 20% Boosted By COVID-19 Treatment; Prepares For Spin-Off
GlaxoSmithKline Plc's (NYSE: GSK) turnover was  
Via Benzinga
RedHill Biopharma's COVID-19 Antiviral Cuts Mortality By 70% In Remdesivir Treated Patients
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced results from two recently completed prespecified analyses from the oral opaganib Phase 2/3 study in hospitalized severe COVID-19.  
Via Benzinga
Why Jim Cramer Believes Loves Berkshire Hathaway And Rivian
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is not a fan of Gilead Sciences, Inc. (NASDAQ: GILD). "They have what I call big hat, no cattle, and I like ones that have cattle," he added. 
Via Benzinga
5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet
Joe Biden is redoubling his efforts to fight cancer with a new "cancer cabinet." Here are the biotech stocks to buy that can benefit. 
Via InvestorPlace
GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead
GlaxoSmithKline plc (NYSE: GSK) has settled a patent dispute between ViiV Healthcare and Gilead Sciences Inc (NASDAQ: GILD). 
Via Benzinga
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates
Gilead Sciences Inc (NASDAQ: GILD) posted  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Epizyme (NASDAQ:EPZM) shares incr... 
Via Benzinga
Gilead Stock Dives After Two Major Charges Dig Into Fourth-Quarter Earnings
Gilead shares toppled after hours on lighter-than-expected fourth-quarter profit. 
Via Investor's Business Daily
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Will Moderna Sidestep The Looming Sales Cliff After FDA Approves Covid Shot?
Currently, analysts expect Moderna sales to drop off after 2022. 
Via Investor's Business Daily
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way
Sierra Oncology spent just $3 million up front to acquire momelotinib. 
Via Investor's Business Daily
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results... 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
32 33 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.